科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: The discovery of adult endothelial progenitor cells ( EPC) offers potential for vascular regenerative therapies. The expression of CD34 and VEGFR2 by EPC indicates a close relationship with haematopoietic progenitor cells ( HPC), and HPC- rich sources have been used to treat cardiac and limb ischaemias with apparent clinical benefit. However, the laboratory characterisation of the vasculogenic capability of potential or actual therapeutic cell autograft sources is uncertain since the description of EPC remains elusive. Various definitions of EPC based on phenotype and more recently on colony formation ( CFU- EPC) have been proposed.
Methods: We determined EPC as defined by proposed phenotype definitions ( flow cytometry) and by CFU- EPC in HPC- rich sources: bone marrow ( BM); cord blood ( CB); and G- CSF- mobilised peripheral blood ( mPB), and in HPC- poor normal peripheral blood ( nPB).
Results: As expected, the highest numbers of cells expressing the HPC markers CD34 or CD133 were found in mPB and least in nPB. The proportions of CD34+ cells co- expressing CD133 is of the order mPB> CB> BM approximate to nPB. CD34+ cells co- expressing VEGFR2 were also most frequent in mPB. In contrast, CFU- EPC were virtually absent in mPB and were most readily detected in nPB, the source lowest in HPC.
Conclusion: HPC sources differ in their content of putative EPC. Normal peripheral blood, poor in HPC and in HPC- related phenotypically defined EPC, is the richest source of CFU- EPC, suggesting no direct relationship between the proposed EPC immunophenotypes and CFU- EPC potential. It is not apparent whether either of these EPC measurements, or any, is an appropriate indicator of the therapeutic vasculogenic potential of autologous HSC sources.
- 出版日期2007-7-18
